Therefore, our present CSF study highlights that cognitive deficits complained by LLD patients were unrelated to AD-like neurodegeneration, by reason of LLD patients showed no pathological changes in Aβ42 and tau proteins contents, but a CSF biomarker profile similar to non-demented controls (Lee et al., 1991). The gene discussed is MAPT; the disease is Alzheimer disease.